US Patent

US11571518 — Emergency devices

Method of Use · Assigned to Adamis Pharmaceuticals Corp · Expires 2041-06-14 · 15y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects emergency syringe devices containing a therapeutic dose of at least one drug, including Naloxone Hydrochloride, for overdose treatment.

USPTO Abstract

Described herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug to be used in a drug or substance overdose.

Drugs covered by this patent

naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3515`	—	naloxone-hydrochloride

Patent Metadata

Patent number: US11571518
Jurisdiction: US
Classification: Method of Use
Expires: 2041-06-14
Drug substance claim: No
Drug product claim: Yes
Assignee: Adamis Pharmaceuticals Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.